Post-transplant.lymphoproliferative disorders

被引：91

作者：

LaCasce, Ann S. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA

来源：

ONCOLOGIST | 2006年 / 11卷 / 06期

关键词：

PTLD; early lesion; polymorphic PTLD; monomorphic PTLD;

D O I：

10.1634/theoncologist.11-6-674

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Post-transplant lymphoproliferative disorder is the most common malignancy, with the exception of skin cancer, after solid organ transplantation in adults. The incidence varies according to the transplanted organ and is often associated with Epstein-Barr virus. Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease.

引用

收藏

页码：674 / 680

页数：7

相关论文

共 60 条

[1]

Badley A D, 1996, Liver Transpl Surg, V2, P375, DOI 10.1002/lt.500020508

[2]

Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort [J].

Baiocchi, OCG ;

Colleoni, GWB ;

Caballero, OL ;

Vettore, AL ;

Bulgarelli, A ;

Dalbone, MA ;

Granato, CFH ;

Franco, MF ;

Pestana, JOM .

LEUKEMIA & LYMPHOMA, 2005, 46 (04) :533-539

[3]

Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction [J].

Benden, C ;

Aurora, P ;

Burch, M ;

Cubitt, D ;

Lloyd, C ;

Whitmore, P ;

Neligan, SL ;

Elliott, MJ .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (12) :2103-2108

[4]

Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].

Benkerrou, M ;

Jais, JP ;

Leblond, V ;

Durandy, A ;

Sutton, L ;

Bordigoni, P ;

Garnier, JL ;

Le Bidois, J ;

Le Deist, F ;

Blanche, S ;

Fischer, A .

BLOOD, 1998, 92 (09) :3137-3147

[5]

THERAPY FOR TRANSPLANT-RELATED LYMPHOPROLIFERATIVE DISEASES [J].

BENKERROU, M ;

DURANDY, A ;

FISCHER, A .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (02) :467-475

[6]

Boubenider S, 1997, J NEPHROL, V10, P136

[7]

Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease [J].

Burns, DM ;

Crawford, DH .

BLOOD REVIEWS, 2004, 18 (03) :193-209

[8]

Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients [J].

Bustami, RT ;

Ojo, AO ;

Wolfe, RA ;

Merion, RM ;

Bennett, WM ;

McDiarmid, SV ;

Leichtman, AB ;

Held, PJ ;

Port, FK .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) :87-93

[9]

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression [J].

Caillard, S ;

Dharnidharka, V ;

Agodoa, L ;

Bohen, E ;

Abbott, K .

TRANSPLANTATION, 2005, 80 (09) :1233-1243

[10]

Molecular histogenesis of posttransplantation lymphoproliferative disorders [J].

Capello, D ;

Cerri, M ;

Muti, G ;

Berra, E ;

Oreste, P ;

Deambrogi, C ;

Rossi, D ;

Dotti, G ;

Conconi, A ;

Viganò, M ;

Magrini, U ;

Ippoliti, G ;

Morra, E ;

Gloghini, A ;

Rambaldi, A ;

Paulli, M ;

Carbone, A ;

Gaidano, G .

BLOOD, 2003, 102 (10) :3775-3785

← 1 2 3 4 5 6 →